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OBJECTIVE—Loss of thrombospondin (TSP)-1 in pancreatic
islets has been shown to cause islet hyperplasia. This study tested
the hypothesis that endothelial-derived TSP-1 is important for b-cell
function.
RESEARCH DESIGN AND METHODS—Islet function was
evaluated both in vivo and in vitro. Messenger RNA and protein
expression were measured by real-time PCR and Western blot,
respectively. The role of endothelial-derived TSP-1 for b-cell func-
tion was determined using a transplantation design in which re-
cipient blood vessels either were allowed to grow or not into the
transplanted islets.
RESULTS—TSP-1–deﬁcient mice were glucose intolerant, de-
spite having an increased b-cell mass. Moreover, their islets had
decreased glucose-stimulated insulin release, (pro)insulin bio-
synthesis, and glucose oxidation rate, as well as increased ex-
pression of uncoupling protein-2 and lactate dehydrogenase-A
when compared with control islets. Almost all TSP-1 in normal
islets were found to be derived from the endothelium. Transplan-
tation of free and encapsulated neonatal wild-type and TSP-1–
deﬁcient islets was performed in order to selectively reconstitute
with TSP-1–positive or –negative blood vessels in the islets and
supported that the b-cell defects occurring in TSP-1–deﬁcient
islets reﬂected postnatal loss of the glycoprotein in the islet en-
dothelial cells. Treatment of neonatal TSP-1–deﬁcient mice with
the transforming growth factor (TGF)b-1–activating sequence of
TSP-1 showed that reconstitution of TGFb-1 activation prevented
the development of decreased glucose tolerance in these mice.
Thus, endothelial-derived TSP-1 activates islet TGFb-1 of impor-
tance for b-cells.
CONCLUSIONS—Our study indicates a novel role for endothe-
lial cells as functional paracrine support for pancreatic b-cells.
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T
he vasculature traditionally has been regarded
mainly as a transport system that mediates met-
abolic exchange between tissues and blood.
However, aside from its transport functions,
blood-vessel cells have, in recent years, been recognized to
be able to interact with and differentiate adjacent paren-
chymal cells through paracrine signals during development
(1–3). Moreover, they seem to be able to provide mitotic
signals during adulthood (4).
To date, there have been few studies (5–7) on whether
endothelial cells may directly affect parenchymal function.
Islets of Langerhans in the adult have a uniquely dense
network of capillaries maintained by constant exposure to
vascular endothelial growth factor (VEGF)-A secreted from
adjacent b-cells (8,9). The high number of islet capillaries
results in each b-cell being located directly adjacent to at
least one endothelial cell (10), thereby enabling a direct in-
teraction with endothelium-derived factors. The importance
of islet endothelial factors in the control of b-cell pro-
liferation recently has been studied, and both endothelium-
derived hepatocyte growth factor (11) and the vascular
membrane component laminin (7) seem to be important in
this context.
In the current study, we investigated products of puri-
ﬁed and isolated islet endothelial cells and thereby found
the glycoprotein thrombospondin (TSP)-1 to be highly ex-
pressed in the endothelium of islets. TSP-1 is mainly known
for its antiangiogenic properties (12) but also may alter the
morphology of pancreatic islets and functions as a major
activator of transforming growth factor (TGF)b-1 (13). Be-
cause TGFb-1 is known to modulate b-cell function (14,15),
we tested the hypothesis that endothelial cell–derived TSP-1
is important to maintain b-cell function postnatally.
RESEARCH DESIGN AND METHODS
TSP-1–deﬁcient (
2/2) mice were generated by homologous recombination
in 129/Sv-derived embryonic stem cells implanted in C57BL/6 blastocysts.
Chimeras were bred to C57BL/6 mice, and heterozygotes were backcrossed
(N9) to a C57BL/6 genetic background (99.6%) (16). Wild-type TSP-1 (
+/+)o r
TSP-1–deﬁcient mice aged 0, 10–12, or 52 weeks were allocated to the different
studies. All experiments were approved by the animal ethics committee for
Uppsala University.
Chemicals. All chemicals were purchased from Sigma-Aldrich (Irvine, U.K.),
unless otherwise mentioned.
Islet morphology. Pancreata from 10- to 12-week-old wild-type and TSP-1–
deﬁcient mice were retrieved, weighed, ﬁxed in 10% (vol/vol) formaldehyde
and embedded in parafﬁn. Sections (5 mm thick) of the pancreata were stained
with a guinea pig antibody for insulin (ICN Biomedicals, Aurora, OH) (17) and
counterstained with hematoxylin. For each animal, $10 tissue sections from
all parts of the pancreas were randomly chosen and evaluated. The fraction of
the pancreas composed of endocrine tissue was measured by a direct point-
counting method (18) and used for calculation of the endocrine mass com-
pensating for differences in pancreatic weight between animals. The b-cell
fraction of the islets in wild-type and TSP-1–deﬁcient mice was estimated with
a similar point-counting technique. The area of the investigated islets was de-
termined using a computerized system for morphometry (Scion Image, Scion,
MD). A total of at least 1,089 intersections were counted in each pancreas.
Oxygen tension measurements. Oxygen tension in native pancreatic islets of
10- to 12-week-old wild-type and TSP-1–deﬁcient mice were recorded in vivo,
as previously described (19).
Twenty-four–hour blood glucose measurements. Blood glucose measure-
ments were performed at 2-h intervals for 24 h on blood obtained from the cut
tip of the tail of 10- to 12-week-old wild-type and TSP-1–deﬁcient mice using test
reagent strips (Freestyle; Baxter Travenol, Deerﬁeld, IL). The animals were fed
ad libitum during the experiments.
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ORIGINAL ARTICLEGlucose and insulin tolerance tests. Glucose or insulin tolerance tests were
performed on 10- to 12- or 52-week-old wild-type and TSP-1–deﬁcient mice, as
described previously (20).
Islet isolation and culture. Pancreatic islets from neonatal or 10- to 12-week-
o l dw i l d - t y p ea n dT S P - 1 –deﬁcient C57BL/6 mice, as well as adult WF rats, were
prepared by collagenase digestion (21) and maintained free ﬂoating in groups of
150 islets at 37°C (air/CO2,9 5 : 5 )f o r1 –3 days in 5 mL culture medium composed
of RPMI-1640 medium supplemented with 2 mmol/L L-glutamine, 11 mmol/L
glucose, and 10% (vol/vol) FCS.
Islet functional tests. The capacity of isolated islets from 10- to 12-week-old
wild-type or TSP-1–deﬁcient mice for glucose-stimulated or potassium chloride
(30 mmol/L)-stimulated insulin release, glucose-stimulated proinsulin bio-
synthesis, and glucose oxidation was determined in batch-type experiments
(for protocol see [6]).
Electron microscopy. Islets isolated from 10- to 12-week-old wild-type or TSP-
1–deﬁcient mice were prepared for electron microscopy (22). Ultrastructural
studies of mitochondria and endoplasmic reticulum were performed using an
H-7100 transmission electron microscope (Hitachi, Tokyo, Japan).
Determination of reactive oxygen species. The production of reactive
oxygen species (ROS) in groups of 50 wild-type or TSP-1–deﬁcient islets in
response to 11.1 or 28 mmol/L glucose with or without the presence of H2O2
was estimated by ﬂow cytometry, as previously described (23).
Gene expression. Whole islets from 10- to 12-week-old wild-type and TSP-1–
deﬁcient mice were used to investigate changes in mRNA expression induced
by TSP-1 deﬁciency. RNA was isolated using Ultraspec (Biotecx Laboratories,
Houston, TX), and cDNA synthesis was performed with random nonamers
(Sigma-Aldrich) and reverse transcriptase Moloney murine leukemia virus H
–
(Finnzymes, Espoo, Finland). Ampliﬁcation was obtained with a Lightcycler
system (Roche-Diagnostic, Lewes, U.K.) using a DyNAmo Capillary SYBR
Green qPCR kit (Finnzymes). For the primer sequences used, see Table 1. All
values were normalized against b-actin.
Western blot and lactate analysis. Islets from 10- to 12-week-old wild-type
and TSP-1–deﬁcient mice were prepared for Western blot, and the protein
expression analyzed, as previously described (24). For antibodies used, see
Table 1. All values were normalized against total extracellular signal–regulated
kinase (ERK). Lactate production from incubated wild-type and TSP-1–deﬁcient
islets were determined, as described previously (25).
Isolation and culture of islet endothelial cells. Outgrowth of islet mesen-
chymal cells was stimulated using our previously described protocol (11,26). In
brief, 20 hand-picked, apparently clean islets isolated from wild-type C57BL/6
mice 10–12 weeks old, or from WF rats of corresponding age, were transferred
onto a collagen matrix (1.8 mg collagen type 1 per mL; Collagen, Nutacon,
Leimuden, the Netherlands) in a 24-well culture dish. The islets were cultured at
37°C (air/CO2, 95:5) in 1 mL culture medium composed of RPMI-1640 medium
supplemented with 11 mmol/L glucose, 20% (vol/vol) FCS, 100 mg endothelial
cell growth supplement, and 2 mmol/L L-glutamine. Vascular sprouts grew out
from the islets, and the cells were detached with 0.25% (wt/vol) trypsin (Sigma-
Aldrich) for ,5 min at 37°C. The suspension was washed twice in culture
medium. The endothelial cells were extracted from the cell suspension by
a dynabead method (27). By the use of Bandeiraea (Griffonia) simplicifolia
(BS-1)-coated dynabeads, endothelial cells were separated from contaminating
cells, achieving a purity of .90% (11,26). The detailed characterization of the
endothelial cells has been described previously (6,26).
Isolation of b-cells. Islets isolated from wild-type C57BL/6 mice were
dissociated with trypsin (Sigma-Aldrich), followed by cell sorting using a
ﬂuorescence-activated cell sorter (FACS Calibur; Becton Dickenson, San Jose,
CA). The cells were sorted according to autoﬂuorescence at 530 nm, which
generates a purity of ~95% b-cells (28).
Islet cellular localization of TSP-1. Islet endothelial cells, b-cells or intact
islets from wild-type C57BL/6 mice, islet endothelial cells or intact islets from
WF rats, and cells from the mouse and rat insulinoma cell lines bTC-6 and INS-1
were washed with PBS and analyzed for TSP-1 mRNA expression (compared
with above). In these experiments, b-actin was used as a reference gene;
however, normalization against TATA-box–binding protein (TBP) gave similar
results. For primer sequences used, see Table 1.
Importance of endothelial-derived TSP-1. To separately evaluate the
contribution of islet endothelial-derived TSP-1 for b-cell function, we per-
formed transplantation experiments of neonatal pancreatic islets that, after
isolation from wild-type and TSP-1–deﬁcient mice, had been cultured for
1 day. Wild-type islets were transplanted into either 10- to 12-week-old wild-
type or TSP-1–deﬁcient mice. Likewise, islets derived from TSP-1–deﬁcient
mice were implanted into either wild-type or TSP-1–deﬁcient mice. For trans-
plantation, groups of 150 neonatal wild-type or TSP-1–deﬁcient islets were
syngeneically implanted beneath the capsule of the left kidney in wild-type
or TSP-1–deﬁcient C57BL/6 mice. One month posttransplantation, glucose-
stimulated insulin secretion of the islet grafts was evaluated by vascular
perfusion ex vivo (29,30).
Although precultured and nonencapsulated islets mainly obtain their new
vascular system from the recipient after transplantation (19,31), islets en-
capsulated prior to transplantation lack such blood vessels. A rationale for
transplanting encapsulated islets was to provide a control for the possible
inﬂuence of nonvascular systemic inﬂuences on b-cell function in TSP-1–
deﬁcient mice. Microencapsulated islets were implanted intraperitoneally,
instead of beneath the renal capsule, because the capsules are more easily
retrieved for in vitro experiments from the peritoneal cavity. Microcapsules
composed of alginate (guluronic acid 73%/mannuronic acid 27%; Pronova
Biopolymer, Drammen, Norway), in which divalent cations such as Ca
2+
crosslink guluronic acid blocks and thus form a gel, were produced as fol-
lows (32,33). The microencapsulated islets were immediately transplanted
intraperitoneally into 10- to 12-week-old wild-type or TSP-1–deﬁcient mice.
The recipient mice were anesthetized by inhalation of isoﬂurane (32). A small
incision was made in the skin, and the peritoneal membrane and the capsules
TABLE 1
Primer sequences and antibodies
Gene/antibody Sense primer (59–39) Antisense primer (59–39) Genebank accession no.
b-Actin GCTCTGGCTCCTAGCACC CCACCGATCCACACAGAGTACTTG NM_007393
Glucokinase AGGCACGAAGACATAGACAAG ACCACATCCATCTCAAAGTCC NM_010292
Insulin CCATCAGCAAGCAGGTTAT GGGTGTGTAGAAGAAGCCA NM_008386
LDH-A GGTTGCAATCTGGATTCAGCG TCAGTGCCCAGTTCTGGGTTA NM_010699
Mitochondrial glycerol
phosphate dehydrogenase-2 GTTGAAGTGAGAAGAGGGGATG GACAAGCCTGATGTAGAGTGTG NM_010274
Pyruvate carboxylase CTACACCAACTACCCTGACAAC GCTAAGCCCATGTAGTACTCC NM_008797
PDX-1 GGTGCCAGAGTTCAGCGCTA TTGTTTTCCTCGGGTTCCGC NM_008814
TBP ACCCTTCACCAATGACTCCTATG ATGATGACTGCAGCAAATCGC NM_013684
TSP-1 (mouse) GGAACGGAAAGACAACACTG AGTTGAGCCCGGTCCTCTTG NM_01158
TSP-1 (rat) GCCGATTCCAGATGATTCC ACCCGAAAACAAAGCCAG NM_001013062
UCP-2 AGCCTACAAGACCATTGCACG CAGAAGTGAAGTGGCAAGGGA NM_011671
ERK antibody
LDH-A antibody
PDX-1 antibody
UCP-2 antibody
All primers were ordered from MWG Biotech (Ebersberg, Germany). Antibodies directed toward LDH-A and PDX-1 were purchased from Cell
Signaling (Beverly, MA), whereas ERK antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Three different UCP-2
antibodies obtained from Santa Cruz Biotechnologies, Millipore (Billerica, MA), and Fitzgerald Industries International (North Acton, MA),
respectively, were used.
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sutures were required to close the peritoneal membrane, and two to three
sutures closed the skin. One month posttransplantation, animals were killed
by cervical dislocation; the capsules were retrieved by ﬁlling the abdominal
cavity with ~5–6 mL cold saline supplemented with 2 mmol/L Ca
2+ (balanced
salt solution; SBL Vaccindistribution, Stockholm, Sweden) to wash out the cap-
sules. Retrieved capsules were used for measurements of glucose-stimulated
insulin release (compared with Supplementary Data 2), with each observation
representing one animal.
Treatments with TGFb-1–activating recombinant proteins. Two-day-old
neonatal wild-type and TSP-1–deﬁc i e n tm i c ew e r ei n j e c t e dw i t he i t h e rt h e
TGFb-1–activating recombinant protein that is the second type 1 repeat of
TSP-1 (TSR2+RFK) or the control protein (TSR2+QFK) (34). The proteins were
administered intraperitoneally every morning at a dose of 1 mg/kg. Vehicle
(10 mmol/L Tris-HCl, pH 7.6, in 500 mmol/L NaCl)-injected wild-type and
TSP-1–deﬁcient animals served as additional controls. Animals were treated
for 3 weeks before glucose tolerance tests. Glucose tolerance tests were
performed as described in Supplementary Data 1, but glucose was admin-
istered intraperitoneally instead of intravenously because of the small size of
the animals.
Statistical analysis. Values are expressed as the means 6 SE. When only two
groups were compared, an unpaired or paired Student t test was used. Mul-
tiple comparisons between parametric data were performed using ANOVA and
a Bonferronni post hoc test. Gene expression data were compared using the
Mann-Whitney rank-sum test. For all comparisons, P values , 0.05 were
considered statistically signiﬁcant.
RESULTS
Morphology of islets in TSP-1–deﬁcient mice. Body
weights and pancreas weights were similar in 10- to 12-
week-old wild-type and TSP-1–deﬁcient mice. Islet and
b-cell masses were higher in TSP-1–deﬁcient mice when
compared with controls (Fig. 1A–D).
Oxygen tension in islets in TSP-1–deﬁcient mice.
Oxygen tension levels, as measured in vivo, were similar
in pancreatic islets of 10- to 12-week-old wild-type and
TSP-1–deﬁcient animals (38.0 6 1.6 vs. 40.4 6 1.3 mmHg,
respectively, n = 7 animals in each group).
Glucose and insulin tolerance tests. Ten- to 12-week-
old TSP-1–deﬁcient mice had normal blood glucose con-
centrations throughout the day (Fig. 2A and B) but showed
impaired glucose tolerance after intravenous glucose ad-
ministration (Fig. 2C and D). Serum insulin levels both
before and 10 min after glucose administration in the
glucose tolerance test were lower in TSP-1–deﬁcient mice
when compared with wild-type mice (Fig. 2E and F). There
were no differences in glucose tolerance and insulin se-
cretion between males and females or between 10- to 12-
and 52-week-old TSP-1–deﬁcient mice (data not shown).
Insulin tolerance tests revealed no differences between
wild-type and TSP-1–deﬁcient mice (Fig. 2G and H).
Islet function in vitro. At low glucose concentrations
(1.67 mmol/L), pancreatic islets derived from 10- to 12-
week-old TSP-1–deﬁcient mice secreted more insulin than
controls (Fig. 3A). However, in response to an increased
glucose concentration (16.7 mmol/L), there was an impaired
insulin response. Potassium chloride (30 mmol/L) induced
similar insulin release from wild-type and TSP-1–deﬁcient
islets (ratios 22.5 6 4.9 [n = 4] vs. 22.4 6 9.8 [n = 4] for wild-
type and TSP-1–deﬁcient islets, respectively, in high and
low potassium concentrations). Islet insulin content was
similar when comparing TSP-1–deﬁcient islets and wild-
type islets, and that held true also when compensating for
FIG. 1. Endocrine (A) and b-cell (B) mass of wild-type (Wt; ■) and TSP-1 (
2/2)( □) mice. C and D: Pancreata obtained from a wild-type (C)o r
TSP-1 (
2/2)( D) mouse, respectively, and stained for insulin. Scale bar 300 mm. Values in A and B are means 6 SE for ﬁve to six experiments in
each group. *P < 0.05 when compared with wild-type mice. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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sulin biosynthesis was impaired in the TSP-1–deﬁcient
islets (Fig. 3C), as was the rate of glucose oxidation at high
glucose (Fig. 3D).
Ultrastructural analysis and ROS generation. No
changes in the number or structure of mitochondria, or of
the endoplasmic reticulum, could be observed by electron
microscopy in b-cells of TSP-1–deﬁcient islets when
compared with wild-type islets (Supplementary Data 1).
Likewise, there was no difference in ROS production be-
tween wild-type and TSP-1–deﬁcient islets after exposure
to 11.1 or 28 mmol/L glucose (Supplementary Data 2).
Islet mRNA and protein expression. Islets derived from
10- to 12-week-old TSP-1–deﬁcient mice had an increased
mRNA expression of both lactate dehydrogenase (LDH)-A
and uncoupling protein (UCP)-2 when compared with
control islets (Fig. 4A and B). Moreover, they showed
a tendency for decreased gene expression of pancreatic
duodenal homeobox gene (PDX)-1 (P = 0.076) (Fig. 4C). In
contrast, there were no differences in the gene expres-
sion of pyruvate carboxylase, glucokinase, mitochondrial
glycerol-phosphate dehydrogenase-2, and insulin (data
not shown). Immunoblotting conﬁrmed increased protein
levels of LDH-A and decreased levels of PDX-1, whereas
lack of speciﬁc antibodies (cross-reactivity) prevented
analysis of UCP-2 protein (Fig. 4D and E). Lactate concen-
trations were higher in the medium of incubated TSP-1–
deﬁcient islets than control islets (Fig. 4F).
Expression of TSP-1 in islets. Islet endothelial cells of
both 10- to 12-week-old mice (Fig. 5A) and rats (Fig. 5B)
had more than 15 times higher expression of mRNA for
TSP-1 than whole islets and puriﬁed b-cells. In b-cell lines
derived from mouse (bTC-6) and rat (INS-1) no TSP-1
mRNA expression at all could be detected.
Importance of endothelium-derived TSP-1. Nonencap-
sulated neonatal islets were investigated in perfusion
experiments 1 month after syngeneic transplantation be-
neath the renal capsule of adult mice. When challenged with
high glucose (16.7 mmol/L), wild-type islets transplanted
into TSP-1–deﬁcient mice secreted much less insulin than
when implanted to wild-type mice (Fig. 6A and B). More-
over, TSP-1–deﬁcient islets implanted into TSP-1–deﬁcient
mice secreted much lower amounts of insulin in response
to glucose than if instead implanted to wild-type mice (Fig.
6A and B). In fact, TSP-1–deﬁcient islets implanted to wild-
type mice responded to glucose as rigorously as the wild-
type islets implanted to the same hosts (Fig. 6A and B).
Encapsulated neonatal wild-type islets were investigated
in batch-type experiments after retrieval 1 month after
syngeneic intraperitoneal transplantation into adult mice.
When challenged with high glucose (16.7 mmol/L), wild-type
islets secreted similar amounts of insulin when retrieved
from TSP-1–deﬁcient or wild-type hosts (Fig. 6C). In con-
trast, TSP-1–deﬁcient islets responded poorly to a high
glucose concentration irrespective of whether they were
retrieved from the wild-type or TSP-1–deﬁcient hosts
(Fig. 6C).
Treatment with a TGFb-1–activating protein. To ex-
plore the role of TSP-1 as an activator of TGFb-1, wild-type
and TSP-1–deﬁcient mice were treated with recombinant
proteins that contain the second type 1 repeat of TSP-1.
The wild-type recombinant protein (TSR2+RFK) includes
the sequence RFK, which is essential for activation of
TGFb-1 by TSP-1 (35). The control recombinant protein is
identical except that the ﬁrst arginine in the sequence is
mutated to glutamine, rendering the protein incapable of
activating TGFb-1. In wild-type mice, there were no dif-
ferences in response to a glucose load between animals
FIG. 2. Functional characteristics in vivo of wild-type (Wt; ● or ■) and TSP-1 (
2/2)( ○ or □) mice. A: Blood glucose during 24 h. B: Area under the
curve (AUC) for blood glucose measurements during 24 h. C: Intravenous glucose tolerance test. D: AUC for blood glucose concentrations during
the intravenous glucose tolerance test. E and F: Serum insulin before (E) and 10 min after (F) glucose injection in the intravenous glucose
tolerance test. G: Insulin tolerance test. H: Total AUC for blood glucose concentrations during the insulin tolerance test. Values are means 6 SE
for 5–12 experiments in each group. *P < 0.05 when compared with wild-type mice. Tot, total.
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or vehicle only (Fig. 7A and C). In contrast, neonatal TSP-1–
deﬁcient mice treated for 3 weeks with the TGFb-1–
activating recombinant protein (TSR2+RFK) responded
better in the glucose tolerance tests than corresponding
mice treated with TSR2+QFK or vehicle only (Fig. 7B and C).
Treatment with TSR2+RFK prevented the development of
decreased glucose tolerance in TSP-1–deﬁcient mice when
compared with wild-type mice (Fig. 7C).
DISCUSSION
In the current study, we sought to examine the cell-speciﬁc
expression and functional importance of the glycoprotein
TSP-1 in pancreatic islets. TSP-1 is an extracellular matrix–
bound factor and was the ﬁrst naturally occurring inhibitor
of angiogenesis to be reported (36). It regulates angio-
genesis through binding to the CD36 receptor on endo-
thelial cells by inhibition of matrix metalloproteinase-9 and
by activation of TGFb-1 (37). It was later shown to be in-
volved in many other processes in the body, including the
regulation of extracellular matrix function, blood clot for-
mation, and immune responses (13,37–39).
When TSP-1–deﬁcient mice were ﬁrst characterized,
they were found to have an almost normal morphological
phenotype (13). An increased number of blood vessels
were, however, discerned in the pancreatic islets of such
mice, whereas blood vessel numbers in their exocrine
tissue were unaffected (13). The islet blood vessels also
seem to be fully functional, as assessed in the present ar-
ticle by islet oxygen tension measurements. Indeed, an
additional increase in oxygen tension when compared with
wild-type mice is impossible because of already achieved
equilibrium with pO2 in venous blood (compared with
[40]). It is interesting to note that the increased islet blood
vessel density was associated with islet hyperplasia. The
importance of TSP-1 for islet function has, however, not
been investigated. In the current study, we observed a de-
creased glucose tolerance in TSP-1–deﬁcient mice, despite
their increased islet and b-cell mass. However, the im-
paired glucose tolerance did not seem to reﬂect increased
insulin resistance because a decreased insulin response to
a glucose load was observed both in vivo and in vitro.
There did not seem to be a defect in b-cell ATP-sensitive
K+ channel or postchannel activity because the islets
responded normally to high potassium levels. However,
a more detailed investigation of isolated TSP-1–deﬁcient
islets showed that they had an impaired capacity to oxi-
date glucose, which indicates a perturbed mitochondrial
function, although ultrastructural analysis showed normal
mitochondria. Other changes in mitochondrial function
were indicated by the gene expression studies, in which
TSP-1–deﬁcient islets were observed to have an upregula-
tion of UCP-2. UCP-2 may uncouple mitochondrial oxidative
respiration by catalyzing a mitochondrial inner-membrane
H
+ leak that bypasses ATP synthase leading to decreased
glucose-induced ATP production and a decreased ability
of glucose to inhibit ATP-sensitive K+ channels (41). Be-
cause of the cross-reactivity of all tested antibodies, this
could, however, not be conﬁrmed at the protein level. Ad-
ditional functional defects may be caused by the increased
LDH-A activity in the TSP-1–deﬁcient islets, which enhances
catalyzation of pyruvate into lactate. Increased lactate
production in TSP-1–deﬁcient islets also was found. This
FIG. 3. Functional characteristics in vitro of wild-type (Wt; ■)a n dT S P - 1(
2/2)( □) islets. A: Glucose-stimulated insulin release. B:I s l e ti n s u l i n
content. C: (Pro)insulin biosynthesis as percentage of total protein biosynthesis. D: Glucose oxidation. Values are means 6 SE for six
experiments in each group. *P < 0.05 when compared with wild-type islets.
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compared with the aerobic metabolism of pyruvate (42).
Moreover, the upregulation of LDH-A in b-cells is likely to
stimulate insulin secretion at low glucose concentrations
(43), which also was observed in the TSP-1–deﬁcient mice.
Functional defects also may be caused by decreased pro-
tein levels of the b-cell differentiation marker PDX-1. It
is interesting to note that despite normal insulin mRNA
levels and insulin content, we found a decreased capacity
for (pro)insulin biosynthesis in TSP-1–deﬁcient islets. Sev-
eral of the functional changes observed in TSP-1–deﬁcient
islets are similar to those described in islets of type 2
diabetic animal models (44). Glucose toxicity seems un-
likely to explain the alterations because although the
animals had a decreased glucose tolerance, their blood
glucose levels during normal life for 24 h when fed ad
libitum were similar to wild-type animals. Likewise, no
increased endoplasmic reticulum stress or ROS activity in
the b-cells of TSP-1–deﬁcient mice seemed to occur.
We and others have previously observed the presence of
TSP-1 in rodent and human islets at both the mRNA
(11,30,45,46) and protein levels (30) and found it to be
expressed at least by the endothelial cells (11,46). Immu-
nohistochemical staining for the presence of TSP-1 has
FIG. 5. TSP-1 mRNA expression in mouse (A)a n dr a t( B) islet cells or whole islets. Values are means 6 SE for four to eight experiments in each
group. *P < 0.05 when compared with islet endothelial cells.
FIG. 4. mRNA and protein expression in wild-type (Wt; ■) and TSP-1 (
2/2)( □) islets. mRNA expression of LDH-A (A), UCP-2 (B), and PDX-1 (C).
D and E: Protein expression of LDH-A and PDX-1. F: Lactate concentration in incubation medium of 30 islets exposed to 95% air/5% CO2 for 2 h at
37°C. Values are means 6 SE for 5–12 experiments in each group. *P < 0.05 when compared with wild-type islets.
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sequestration of the glycoprotein to the islet matrix (11).
To determine the cellular origin of TSP-1 in islets, we an-
alyzed mRNA levels in islet endothelial cells, intact whole
islets, puriﬁed b-cells, and b-cell–derived cell lines. Of in-
terest, in both rats and mice, TSP-1 mRNA levels were high
in the islet endothelial cells, whereas TSP-1 expression in
intact islets and b-cells puriﬁed to ~95% was much lower.
In the mouse and rat b-cell–derived cell lines, bTC-6 and
INS-1, the presence of mRNA for TSP-1 was undetectable.
Although our gene expression analyses indicated that the
majority, if not all, of the TSP-1 in pancreatic islets is of
endothelial origin, it cannot be excluded that the TSP-1
that is important for b-cell function is derived from other
islet cell types. For this purpose, we designed an experi-
ment in which neonatal pancreatic islets from wild-type
and TSP-1–deﬁcient mice were isolated, cultured, and then
transplanted into either adult wild-type or TSP-1–deﬁcient
mice. Islets cultured prior to transplantation have been
previously shown to derive most, if not all, of their new
vascular system from the recipient (19,31) (i.e., TSP-1–
deﬁcient islets implanted to wild-type mice acquire mainly
TSP-1–positive blood vessels and wild-type islets implanted
to TSP-1–deﬁcient mice acquire TSP-1–negative blood ves-
sels). Neonatal islets were used for transplantation because
morphological changes with increased islet mass and vas-
cular density in TSP-1–deﬁcient mice were previously
shown to be prevented by treatment with the TGFb-1–
activating sequence of TSP-1 from birth (13). Of interest, TSP-
1–deﬁcient islets implanted to wild-type mice had normal
function when evaluated 1 month posttransplantation.
In contrast, wild-type islets implanted to TSP-1–deﬁcient
mice displayed similar dysfunction as TSP-1–deﬁcient
islets implanted to TSP-1–deﬁcient mice. These data
suggested that it was indeed TSP-1 in blood vessels that
was of importance for b-cell function; however, the results
could be a result of a possible negative systemic milieu in
TSP-1–deﬁcient mice. We therefore conducted experi-
ments in which the neonatal islets were microencapsulated
before transplantation. This procedure prevents the in-
growth of recipient blood vessels, and, instead, donor blood
vessels remain (Supplementary Data 3) (47). As a result,
encapsulated TSP-1–deﬁcient islets will be deﬁcient of
TSP-1 after transplantation into wild-type mice and only
FIG. 7. Glucose tolerance test of wild-type (A and C)a n dT S P - 1 –deﬁcient (B and C) mice treated with vehicle (● or ■), control protein TSR2+QFK
(▼ or▨), or TGFb-1–activating protein TSR2+RFK (△ or □) daily for 3 weeks. All values are expressed as means 6 SE for four to nine experiments
in each group. *P < 0.05 when compared with vehicle.
FIG. 6. Functional studies 1 month posttransplantation of neonatal islets transplanted nonencapsulated to the renal subcapsular space or in-
traperitoneally after encapsulation. A: Glucose-stimulated insulin release of islet grafts composed of nonencapsulated islets; islets transplanted
from wild-type (Wt) to wild-type animals (●), from wild-type to TSP-1 (
2/2) animals (○), from TSP-1 (
2/2) to wild-type animals (▼), and from
TSP-1 (
2/2) to TSP-1 (
2/2)a n i m a l s( △). B: Area under the curve for insulin secretion from islet grafts composed of nonencapsulated islets during
high-glucose (16.7 mmol/L) conditions, islets transplanted from wild-type to wild-type animals (■), from wild-type to TSP-1 (
2/2) animals (▨), from
TSP-1 (
2/2) to wild-type animals ( ), and from TSP-1 (
2/2) to TSP-1 (
2/2)a n i m a l s( □). C: Glucose-stimulated (16.7 mmol/L) insulin release from
intraperitoneally transplanted encapsulated islets. Values are means 6 SE for four to seven experiments in each group. *P < 0.05 when compared with
wild-type transplanted to wild-type; #P < 0.05 when compared with wild-type transplanted to TSP-1 (
2/2).
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experiments, we observed that TSP-1–deﬁcient islets im-
planted to wild-type mice were dysfunctional 1 month
posttransplantation, whereas wild-type islets implanted to
TSP-1–deﬁcient mice functioned as well as wild-type islets
implanted to wild-type mice. These experiments were
therefore consistent with our hypothesis that TSP-1 de-
rived from endothelial cells is important for b-cell function,
whereas the systemic milieu of TSP-1–deﬁcient mice did
not, per se, seem to be negative for b-cell function.
To investigate whether the islet dysfunction and de-
creased glucose tolerance in the TSP-1–deﬁcient animals
were a result of decreased TGFb-1 activation or whether
they reﬂected other mechanism(s), we treated neonatal
TSP-1–deﬁcient mice with the TGFb-1–activating sequence
of TSP-1 for 3 weeks, followed by glucose tolerance tests.
Treatment with the recombinant protein TSR2+RFK nor-
malized the response of TSP-1–deﬁcient mice to glucose,
whereas no effects at all of the treatment were observed in
wild-type mice. At least part of the effects mediated by
endothelial TSP-1 on glucose homeostasis therefore seems
to be caused by TGFb-1 activation.
In pancreatic islets transplanted to the liver or beneath
the renal capsule (17,19), there is a markedly decreased
vascular density, which opens the possibility that some of
the islet functional defects and gene expression changes
that occurs after transplantation (48–50) may reﬂect im-
paired endothelial cell inﬂuence. Indeed, we recently
showed better revascularization of pancreatic islets par-
tially or totally deﬁcient of TSP-1 (30). When TSP-1 ex-
pression was only transiently decreased by small interfering
RNA during the initial 1- to 2-week revascularization phase,
vascular engraftment was improved and associated with
increased islet graft function when evaluated 1 month
posttransplantation. There also seems to be a deterioration
of the islet vasculature in long-standing experimental type 2
diabetes (45). Nevertheless, identiﬁcation of the molecular
signals required for adequate b-cell function may facilitate
our quest for a better understanding of the pathogenesis of
diabetes. The current study identiﬁes a novel role for islet
endothelium as a functional support for the surrounding
parenchymal cells, the b-cells, by local production of the
glycoprotein TSP-1.
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